Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers

Shire

Status and phase

Completed

Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: Radiolabeled SPD557

Study type

Interventional

Funder types

Industry

Identifiers

NCT01786876

SPD557-107

Details and patient eligibility

About

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C] SPD557 in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly SPD557 or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.

Enrollment

6 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Males ages 18 to 50 years
Have a body mass index (BMI) of ≥18.5 and ≤30 kg/m2
Subject is willing to comply with any applicable contraceptive and sperm donation requirements

Key Exclusion criteria:

Have participated in a [14C]-study within the last 6 months.
Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).
Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
Subjects who report typically having more than 2 bowel movements per day, less than 3 bowel movements per week or those whose bowel habits have changed significantly within 30 days